DTC spending rises 35 percent in first half

Share this article:

DTC ad spending in the first half of 2004 increased nearly 35 percent when compared with the same period last year, and nearly doubled since 2001, according to numbers released late last week by Nielsen Monitor Plus.

According to Nielsen, $2.2 billion was spent on DTC advertising from January-June 2004. That number is 35 percent more than the $1.6 billion spent from January-June 2003 and nearly double the $2.8 billion spent in all of 2001.

Fueled by the advertising that supported the recent launches of Levitra and Cialis, the Rx drug category was the fastest-growing in the January-June period, according to Nielsen.

Additionally, the prescription drug category was the second-largest in terms of dollars spent, with spending expected to continue to rise, according to Nielsen.

Overall, advertising spending in all categories rose 6.4 percent with total spending in all ten major categories reaching close to $19 billion.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...